Overview

A Bioequivalence Study of Subcutaneous (SC) Lebrikizumab Administered by Needle and Syringe or by Prefilled Syringe With Needle Safety Device (PFS-NSD)

Status:
Completed

Trial end date:
2015-10-01

Target enrollment:

Participant gender:

Summary

This study will assess the bioequivalence in healthy participants between a high-concentration formulation of lebrikizumab withdrawn from a vial and administered SC as a single injection by a needle and syringe, and a low-concentration formulation of lebrikizumab administered SC as a single injection via PFS-NSD.

Phase:

Phase 1

Details

Lead Sponsor:

Genentech, Inc.

Treatments:

Antibodies, Monoclonal